Lisocabtagene Maraleucel, Nivolumab, and Ibrutinib for Richter's Transformation
This study is testing a combination of three medications for Richter's transformation, a type of aggressive lymphoma that can develop in people with chronic lymphocytic leukemia (CLL). The medications are lisocabtagene maraleucel (liso-cel), nivolumab, and ibrutinib. Liso-cel uses your own immune cells to fight cancer. Nivolumab helps your immune system slow or stop cancer growth, and ibrutinib is a kinase inhibitor, which blocks signals that cancer cells need to grow. The study aims to see how many patients achieve a complete response (cancer disappears) and to assess any unacceptable side effects. You may be eligible if you are 18 or older and agree to a pre-treatment tumor biopsy. The current recruitment status is unclear.
- Study design
- This is an interventional study with a planned enrollment of 9 participants. It is a Phase II trial, meaning it aims to evaluate the effectiveness and safety of the treatment.
- What's involved
- You would undergo procedures such as tumor biopsies, blood specimen collection, bone marrow biopsies, and PET/CT scans. You would also receive Cyclophosphamide intravenously (IV).
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure complete response for up to 2 years and unacceptable toxicity for up to 28 days after CAR T cell infusion.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT05672173
Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation
Active, Not Recruiting
PHASE2Ages 18+InterventionalTreatmentCity of Hope Medical CenterInvestigator-initiated
~9 participants
Updated 2026-06-09 on ClinicalTrials.gov
What's tested:BiopsyBiospecimen CollectionBone Marrow BiopsyComputed TomographyCyclophosphamideFludarabine
At a glance
Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Complete Response (CR)
Measured over Up to 2 years
+1 more outcome measured
Conditions
NCT05672173
Where you'd take part
This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
City of Hope Medical Center
Duarte, Californiano site contact published
Memorial Sloan Kettering Cancer Center
New York, New Yorkno site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Tanya Siddiqi · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Documented informed consent of the participant
Agreement for confirmatory pre-treatment tumor biopsy
If a patient does not have an easily accessible lymph node to biopsy without excessive risk in the opinion of the investigator, archival biopsy material reviewed by a hematopathologist at the enrolling site for study eligibility and baseline correlatives may be acceptable with approval from the Study principal investigator (PI)
Age: \>= 18 years
Eastern cooperative oncology group (ECOG) \<= 2
Histologically confirmed Richter's Transformation (RT)
Relapsed / refractory following \>=2 prior lines of systemic therapy; OR refractory to first-line chemoimmunotherapy; OR relapsed within 12 months of first line chemoimmunotherapy; OR relapsed after first line of chemoimmunotherapy and not eligible for hematopoietic stem cell transplantation due to comorbidities or age
Eligible to receive liso-cel and ibrutinib per package inserts
Fully recovered from the acute toxic effects (except alopecia) to \<= Grade 1 to prior anti-cancer therapy
Absolute neutrophil count (ANC) \>= 750/mm\^3 unless there is bone marrow involvement
Platelets \>= 75,000/mm\^3 unless there is bone marrow involvement
Total bilirubin =\< 1.5 X ULN (unless has Gilbert's disease)
Aspartate aminotransferase (AST) =\< 2.5 x ULN
Alanine aminotransferase (ALT) =\< 2.5 x ULN
Creatinine clearance of \>= 30 mL/min per 24 hour urine test or the Cockcroft-Gault formula
International Normalized Ratio (INR) OR Prothrombin (PT) =\< 1.5 x ULN
Activated Partial Thromboplastin Time (aPTT) =\< 1.5 x ULN
Left ventricular ejection fraction (LVEF) \>= 40%
Note: To be performed within 28 days prior to Day 1 of protocol therapy.
Seronegative for HCV\*, active HBV (Surface Antigen Negative), and syphilis (RPR)
If positive, Hepatitis C RNA quantitation must be performed OR
If seropositive for HCV or HBV, nucleic acid quantitation must be performed. Viral load must be undetectable
Meets other institutional and federal requirements for infectious disease titer requirements
Note: Infectious disease testing to be performed within 28 days prior to Day 1 of protocol therapy
Women of childbearing potential (WOCBP): negative urine or serum pregnancy test
If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Agreement by females and males of childbearing potential\* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 5 months after the last dose of protocol therapy
Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only)
Exclusion
Subjects who previously received PD1 or PD-L1 inhibitor therapy
Autologous stem cell transplant within 3 months prior to Day 1 of protocol therapy
Allogeneic stem cell transplant within 3 months prior to Day 1 of protocol therapy and no active graft versus host disease (GVHD) or need for immunosuppressants
Chemotherapy, radiation therapy, immunotherapy within 14 days prior to Day 1 of protocol therapy
Strong CYP3A inducers within 14 days prior to Day 1 of protocol therapy
Warfarin within 5 days prior to Day 1 of protocol therapy
Current requirement for oxygen supplementation
Concurrent use of systemic steroids or chronic use of immunosuppressant medications. Recent or current use of inhaled steroids is not exclusionary. Physiologic replacement of steroids (prednisone =\< 7.5 mg /day or equivalent) is allowed throughout the study. Use of "bridging" steroids, to control disease, after leukapheresis and until 3 days prior to CAR T cell infusion, is allowed
Subjects with lymphoma only involving the central nervous system
Class III/IV cardiovascular disability according to the New York Heart Association (NYHA) Classification
Subjects with clinically significant arrhythmia or arrhythmias not stable on medical management within two weeks of screening
Subjects with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system, including seizure disorder
Subjects with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent
Known bleeding disorders (e.g., von Willebrand's disease) or hemophilia
History of stroke or intracranial hemorrhage within 6 months prior to screening
History of other malignancies, except for malignancy surgically resected (or treated with other modalities) with curative intent, basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; non-muscle invasive bladder cancer; malignancy treated with curative intent with no known active disease present for \>= 3 years
Clinically significant uncontrolled illness
Active infection requiring antibiotics
Known history of immunodeficiency virus (HIV)
Females only: Pregnant or breastfeeding
Subjects with an active, known or suspected autoimmune disease. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis) not requiring systemic treatment, well controlled asthma and/or mild allergic rhinitis (seasonal allergies) are eligible
Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
What this trial measures
- Complete Response (CR)Up to 2 years
After cycle 3, the rate and associated 95% binomial exact confidence interval will be estimated.
- Unacceptable Toxicity (UT)Up to 28 days post CAR T cell infusion
Toxicities will be summarized by organ, severity, time of onset and characteristic. UT will be described individually and summarized by count and rate/percentage.